TABLE 2.

Drug susceptibility profiles of drug-resistant VZV Oka strains obtained in vitro

Mutant virus straina	EC50 (μM)b of:
	Cf 1368	Cf 1603	Cf 1742	Cf 1743	ACV	PCV	GCV	BVDU	BVaraU	PFA	PAA	PMEA	PMEDAP	HPMPC	HPMPA
Wild type	0.011 ± 0.004	0.0083 ± 0.0081	0.00019 ± 0.00016	0.00007 ± 0.00013	2.5 ± 1.6	2.2 ± 1.2	1.3 ± 1.3	0.0066 ± 0.0045	0.00015 ± 0.00008	39.8 ± 13.6	50.7 ± 17.9	17.8 ± 9.6	2.3 ± 1.1	0.21 ± 0.35	0.046 ± 0.071
ACVr	>5 ± 0	≥3.56 ± 1.48	>5 ± 0	>5 ± 0	54.6 ± 21.3	26.9 ± 22.1	9.9 ± 13.4	42.0 ± 31.2	≥37.5 ± 28.0	36.0 ± 12.7	45.7 ± 25.7	18.7 ± 17.9	3.0 ± 3.2	0.09 ± 0.10	0.014 ± 0.009
BVDUr	>5 ± 0	≥4.8 ± 0.4	>5 ± 0	>5 ± 0	47.5 ± 27.5	23.0 ± 11.1	5.8 ± 5.5	≥48.6 ± 15.6	>57 ± 0	49.3 ± 17.3	59.3 ± 5.4	27.5 ± 10.5	4.3 ± 3.4	0.17 ± 0.11	0.080 ± 0.090
BVaraUr	>5 ± 0	>5 ± 0	>5 ± 0	>5 ± 0	68.4 ± 25.8	64.8 ± 17.0	6.7 ± 5.5	≥55.5 ± 9.0	>57 ± 0	42.0 ± 6.0	41.4 ± 13.6	26.4 ± 7.0	3.0 ± 0.6	0.10 ± 0.13	0.010 ± 0.008
cf 1368r	>5 ± 0	>5 ± 0	>5 ± 0	>5 ± 0	≥72.2 ± 35.1	18.2 ± 6.7	2.6 ± 0.7	≥40.8 ± 24.9	≥35.5 ± 25.2	38.6 ± 17.3	50.0 ± 24.2	14.3 ± 8.6	3.2 ± 2.4	0.06 ± 0.01	0.043 ± 0.080
cf 1603r	>5 ± 0	>5 ± 0	>5 ± 0	>5 ± 0	≥76.8 ± 25.3	≥70.3 ± 13.8	9.1 ± 7.5	>60 ± 0	>57 ± 0	27.8 ± 8.5	42.4 ± 14.1	21.7 ± 6.8	2.3 ± 0.8	0.15 ± 0.13	0.028 ± 0.037
cf 1742r	>5 ± 0	>5 ± 0	>5 ± 0	>5 ± 0	≥57.9 ± 43.5	65.0 ± 19.4	6.0 ± 5.9	38.0 ± 31.2	>57 ± 0	35.3 ± 2.8	51.7 ± 8.6	13.7 ± 3.9	2.6 ± 0.4	0.29 ± 0.13	0.025 ± 0.021
cf 1743r	>5 ± 0	≥4.8 ± 0.3	>5 ± 0	>5 ± 0	50.0 ± 14.1	43.6 ± 23.2	2.8 ± 1.5	≥43.8 ± 28.2	>57 ± 0	25.5 ± 10.2	28.8 ± 4.4	8.5 ± 2.5	1.3 ± 0.7	0.05 ± 0.06	0.018 ± 0.030

^aSelected for resistance against each of the indicated compounds.

^bEC₅₀s represent means of at least two independent experiments.